- Regulatory Status
- Other Names
- Monokine induced by interferon gamma (MIG), Small inducible cytokine, subfamily B, member 9 (SCYB9)
- Ave. Rating
- Submit a Review
- Product Citations
Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2023. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.
CXCL9 is an inflammatory chemokine initially identified by differential screening of a cDNA library from lymphokine-activated macrophages. CXCL9 is a CXC chemokine and member of the non-ELR (lacking a Glu-Leu-Arg motif in the N-terminal region) CXC chemokine family. CXCL9 shares the CXCR3 receptor with CXCL10 and CXCL11, and these ligands differ in their receptor-binding and -activating properties; CXCL11 is more potent than CXCL10, and CXCL10 is more potent than CXCL9. An alternative spliced variant, CXCR3B, has been described for CXCR3. CXCR3B mediates the angiostatic effect of CXCR3 ligands and is the receptor for PF4 (CXCL4). CXCR3B has been detected in human neoplastic tissues. CXCL9 plays a key role in leukocyte trafficking, acting on activated CD4+ Th1 cells, CD8+ T cells, IL-2 activated T lymphocytes, and NK cells. Also, CXCL9 (as well as CXCL10 and CXCL11) induces angiostatic effects in human microvacular endothelial cells. In addition, CXCL9 enhances T lymphocyte function in alloimmune response; CXCL9 induces T cells proliferation and cytokine production in an experimental model of cardiac allograft vasculopathy. CXCL9 is induced by cytokines, particularly IFNγ during infection, injury, or immunoinflammatory responses, and it can be inactivated by CD26/dipeptidil peptidase IV after truncation by this protease. Amino-terminal truncation of CXCL9 by CD26 impairs lymphocyte chemotaxis, but the antiangiogenic activity is not affected. In rheumatoid arthritis, CXCL9 is synergistically stimulated by TNFα or IL-1a and IFNγ.Product Details
- Human CXCL9, amino acids Thr23 - Thr125 (Accession # NM_002416.1) was expressed in E. coli.
- Molecular Mass
- The 103 amino acid recombinant protein has a predicted molecular mass of approximately 11.7 kD. The DTT-reduced protein migrates at approximately 15 kD, and the non-reduced protein migrates at approximately 18 kD by SDS-PAGE. The N-terminal amino acid is Threonine.
- >98%, as determined by Coomassie stained SDS-PAGE.
- 0.22 µm filtered protein solution is in PBS.
- Endotoxin Level
- Less than 0.01 ng per µg cytokine as determined by the LAL method.
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Bioactivity was measured by its property to chemoattract Baf3-mCXCR3 transfectants in a dose dependent manner. ED50 = 0.04 - 0.32 µg/mL.
- Application Notes
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at firstname.lastname@example.org.
CXCL9 is secreted by monocytes, macrophages, APC, eosinophils, endothelial cells, and B cells. Also, CXCL9 is secreted by fibroblasts in inflammatory conditions.
- CXCL9 plays a key role in leukocyte trafficking, acting on activated CD4+ Th1 cells, CD8+ T cells, IL-2 activated T lymphocytes, and NK cells. Also, CXCL9 (as well as CXCL10 and CXCL11) induces angiostatic effects in human microvacular endothelial cells.
- CXCR3A, CXCR3B
- Cell Type
- Hematopoietic stem and progenitors
- Biology Area
- Cell Biology, Immunology, Signal Transduction, Stem Cells
- Molecular Family
- Antigen References
1. Loetscher M, et al. 1996. J. Exp. Med. 184:963.
2. Lambeir AM, et al. 2001. J. Biol. Chem. 276:29839.
3. Lasagni L, et al. 2003. J. Exp. Med. 197:1537.
4. Whiting D, et al. 2004. J. Immunol. 172:7417.
5. Proost P, et al. 2004. J. Leuko. Biol. 75:777.
6. Gorbachev AV, et al. 2007. J. Immunol. 178: 2278.
7. Rosenblum JM, et al. 2010. J. Immunol. 184:3450.
8. Crawford MA, et al. 2010. PLoS Pathog. 6:e1001199.
- Gene ID
- 4283 View all products for this Gene ID
- View information about CXCL9 on UniProt.org
- Why choose BioLegend recombinant proteins?
• Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
• Greater than 95% Purity or higher, tested on every lot of product.
• 100% Satisfaction Guarantee for quality performance, stability, and consistency.
• Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
• Bulk and customization available. Contact us.
• Learn more about our Recombinant Proteins.
- How does the activity of your recombinant proteins compare to competitors?
We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
- What is the specific activity or ED50 of my recombinant protein?
The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
- Have your recombinants been tested for stability?
Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
- Does specific activity of a recombinant protein vary between lots?
Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
- How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)